We are live on ! Find out more
GILD icon

Gilead Sciences

1,326 hedge funds and large institutions have $139B invested in Gilead Sciences in 2014 Q3 according to their latest regulatory filings, with 126 funds opening new positions, 465 increasing their positions, 615 reducing their positions, and 51 closing their positions.

New
Increased
Maintained
Reduced
Closed

147% more first-time investments, than exits

New positions opened: 126 | Existing positions closed: 51

46% more funds holding in top 10

Funds holding in top 10: 164240 (+76)

20% more capital invested

Capital invested by funds: $116B → $139B (+$22.7B)

5% more funds holding

Funds holding: 1,2621,326 (+64)

24% less repeat investments, than reductions

Existing positions increased: 465 | Existing positions reduced: 615

36% less call options, than puts

Call options by funds: $2.53B | Put options by funds: $3.96B

Holders
1,326
Holders Change
+64
Holders Change %
+5.07%
% of All Funds
38.47%
Holding in Top 10
240
Holding in Top 10 Change
+76
Holding in Top 10 Change %
+46.34%
% of All Funds
6.96%
New
126
Increased
465
Reduced
615
Closed
51
Calls
$2.53B
Puts
$3.96B
Net Calls
-$1.43B
Net Calls Change
-$802M
Name Holding Trade Value Shares
Change
Change in
Stake
RT
426
Rockland Trust
Massachusetts
$14.3M -$502K -5,125 -4%
CTC
427
Central Trust Company
Missouri
$14.3M +$242K +2,470 +2%
FP
428
Foundry Partners
Minnesota
$14.3M -$5.82M -59,425 -31%
SAM
429
Securian Asset Management
Minnesota
$14.2M -$280K -2,858 -2%
CCM
430
Covington Capital Management
California
$14M +$20.1K +205 +0.2%
PP
431
Paloma Partners
Connecticut
$13.9M +$11.9M +121,161 +1,249%
NRS
432
Neville Rodie & Shaw
New York
$13.9M -$124K -1,265 -1%
Creative Planning
433
Creative Planning
Kansas
$13.9M +$6.78M +69,233 +113%
Bank of Nova Scotia
434
Bank of Nova Scotia
Ontario, Canada
$13.7M +$9.89M +101,050 +364%
SM
435
Selkirk Management
New Jersey
$13.7M
DC
436
Deere & Company
Illinois
$13.5M -$549K -5,605 -4%
BIM
437
Bogle Investment Management
Massachusetts
$13.3M +$245K +2,500 +2%
PAM
438
Private Asset Management
California
$13.2M -$328K -3,345 -3%
V
439
Veritable
Delaware
$13.1M +$322K +3,285 +3%
HR
440
Howe & Rusling
New York
$13.1M -$31.2K -319 -0.3%
DCM
441
Decatur Capital Management
Georgia
$13M +$2.38M +24,275 +25%
MCM
442
Munder Capital Management
Michigan
$12.9M -$1.24M -12,615 -9%
Parallax Volatility Advisers
443
Parallax Volatility Advisers
California
$12.8M +$11.8M +120,383 +325,359%
Natixis Advisors
444
Natixis Advisors
Massachusetts
$12.6M +$729K +7,441 +7%
BFS
445
Bradley Foster & Sargent
Connecticut
$12.6M +$273K +2,790 +2%
ICAP
446
Independence Capital Asset Partners
Colorado
$12.6M +$11.6M +118,606 New
KRS
447
Kentucky Retirement Systems
Kentucky
$12.5M +$11.5M +117,603 New
IHM
448
Iguana Healthcare Management
New York
$12.5M +$4.16M +42,500 +57%
FTIOP
449
Fiduciary Trust International of Pennsylvania
Pennsylvania
$12.5M +$1.04M +10,647 +10%
LSERS
450
Louisiana State Employees Retirement System
Louisiana
$12.3M -$441K -4,500 -4%

GILD Hedge Fund Activity: Q3 2014 in Review

1,326 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q3 2014, worth a combined $139B — up 20% from $116B a quarter earlier.

Buyers outnumbered sellers: 126 funds opened new GILD positions and 51 closed out — a net gain of 75 holders — while 465 added to existing stakes and 615 trimmed.

The largest buyer was BNP Paribas Financial Markets, adding an estimated $226M. The largest seller was Capital Research Global Investors, cutting an estimated $1.52B.

  • 1,326 institutional investors held Gilead Sciences (GILD) as of Q3 2014, up from 1,262 in Q2 2014.
  • Funds reported $139B of Gilead Sciences stock for Q3 2014, up 20% quarter-over-quarter.
  • 126 funds opened new Gilead Sciences positions in Q3 2014 and 51 closed out, a net change of +75 holders.
  • The largest Gilead Sciences buyer in Q3 2014 was BNP Paribas Financial Markets, an estimated $226M added.
  • The largest Gilead Sciences seller in Q3 2014 was Capital Research Global Investors, an estimated $1.52B sold.

Based on aggregated 13F filings for Q3 2014.